Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Legend Biotech Corporation Sponsored ADR (LEGN : NSDQ)

• Company Description    Legend Biotech Corporation is a clinical-stage biopharmaceutical company. It engaged in the discovery and development of novel cell therapies for oncology and other indications. The company's lead product consist LCAR-B38M/JNJ-4528, which are in clinical stage. Legend Biotech Corporation is based in Cayman Islands. Number of Employees: 2,609

• Price / Volume Information    Yesterday's Closing Price: $35.64 Daily Weekly Monthly 20 Day Moving Average: 1,838,528 shares Shares Outstanding: 183.76 (millions) Market Capitalization: $6,549.31 (millions) Beta: 0.19 52 Week High: $60.87 52 Week Low: $27.34 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 13.22% 7.08% 12 Week 13.94% -4.41% Year To Date 9.53% 2.59%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2101 COTTONTAIL LANE - SOMERSET,NJ 08873 USA ph: 732-850-5598 fax: - joanne.choi@legendbiotech.com http://www.legendbiotech.com

• General Corporate Information    Officers Ying Huang - Chief Executive Officer Fangliang Zhang - Chairman Jessie Yeung - Chief Financial Officer Ye (Sally) Wang - Director Li Zhu - Director Peer Information Legend Biotech Corporation Sponsored ADR (CORR.) Legend Biotech Corporation Sponsored ADR (RSPI) Legend Biotech Corporation Sponsored ADR (CGXP) Legend Biotech Corporation Sponsored ADR (BGEN) Legend Biotech Corporation Sponsored ADR (GTBP) Legend Biotech Corporation Sponsored ADR (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 52490G102 SIC: 8880 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/08/25 Share - Related Items Shares Outstanding: 183.76 Most Recent Split Date: (:1) Beta: 0.19 Market Capitalization: $6,549.31 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.16 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.00 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 9.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 6.43 Price/Cash Flow: - Price / Sales: 8.99 EPS Growth vs. Year Ago Period: 56.25% vs. Previous Quarter: 53.33% Sales Growth vs. Year Ago Period: 107.52% vs. Previous Quarter: 4.57% ROE 06/30/25 - - 03/31/25 - -21.19 12/31/24 - -23.43 ROA 06/30/25 - - 03/31/25 - -13.47 12/31/24 - -15.04 Current Ratio 06/30/25 - - 03/31/25 - 5.20 12/31/24 - 4.62 Quick Ratio 06/30/25 - - 03/31/25 - 5.07 12/31/24 - 4.54 Operating Margin 06/30/25 - - 03/31/25 - -31.52 12/31/24 - -41.83 Net Margin 06/30/25 - - 03/31/25 - -29.95 12/31/24 - -28.22 Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - -25.21 Book Value 06/30/25 - - 03/31/25 - 5.54 12/31/24 - 5.70 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - 10.61 Debt-to-Equity 06/30/25 - - 03/31/25 - 0.30 12/31/24 - 0.29 Debt-to-Capital 06/30/25 - - 03/31/25 - 23.10 12/31/24 - 22.45

Powered by Zacks Investment Research ©